Markets:

Overview

News

Currencies

International

Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

78.96 -1.47 (-1.83%)

Streaming Delayed Price Updated: 11:31 AM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast ↗

February 28, 2025

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.

Via Benzinga

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 28, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars

February 28, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year...

Via StockStory

Earnings Scheduled For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Where ANI Pharmaceuticals Stands With Analysts ↗

December 11, 2024

Via Benzinga

A Peek at ANI Pharmaceuticals's Future Earnings ↗

November 07, 2024

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Topics Artificial Intelligence Intellectual Property

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

February 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know ↗

October 22, 2024

Via Benzinga

Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights ↗

October 11, 2024

Via Benzinga

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 16, 2025

Via Benzinga

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗

January 16, 2025

Via Benzinga

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential ↗

October 11, 2024

Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial...

Via Benzinga

In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals ↗

September 17, 2024

Via Benzinga

Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts ↗

April 23, 2024

Via Benzinga

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts ↗

March 05, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗

September 11, 2024

Via Benzinga

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

September 11, 2024

From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.

Via Business Wire

ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)

July 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)

July 01, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

June 26, 2024

Via Benzinga

Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close ↗

June 25, 2024

Via Benzinga

Topics Stocks

Why Is Alimera Sciences (ALIM) Stock Up 77% Today? ↗

June 24, 2024

Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.

Via InvestorPlace

Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal ↗

June 24, 2024

ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close...

Via Benzinga

ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 10, 2024

ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Alphabet, Dover And 2 Other Stocks Insiders Are Selling ↗

March 11, 2024

The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.